药品注册申请号：020152
申请类型：NDA (新药申请)
申请人：BRISTOL MYERS SQUIBB
申请人全名：BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 SERZONE NEFAZODONE HYDROCHLORIDE TABLET;ORAL 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Yes No None 1994/12/22 1994/12/22 Discontinued
002 SERZONE NEFAZODONE HYDROCHLORIDE TABLET;ORAL 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Yes No None 1994/12/22 Discontinued
003 SERZONE NEFAZODONE HYDROCHLORIDE TABLET;ORAL 150MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Yes No None 1994/12/22 Discontinued
004 SERZONE NEFAZODONE HYDROCHLORIDE TABLET;ORAL 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Yes No None 1994/12/22 Discontinued
005 SERZONE NEFAZODONE HYDROCHLORIDE TABLET;ORAL 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Yes No None 1994/12/22 Discontinued
006 SERZONE NEFAZODONE HYDROCHLORIDE TABLET;ORAL 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Yes No None 1994/12/22 Discontinued
批准日期，申请提交历史，通知信，药品说明书，审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级；罕用药状态通知信、审评文件、说明书、包装标签备注
2009/03/13 SUPPL-32（补充） Approval Efficacy PRIORITY
2009/03/13 SUPPL-14（补充） Approval Labeling STANDARD
2005/01/12 SUPPL-35（补充） Approval Labeling STANDARD
2004/05/27 SUPPL-34（补充） Approval Labeling STANDARD
2003/05/05 SUPPL-31（补充） Approval Labeling STANDARD
2002/06/20 SUPPL-33（补充） Approval Labeling STANDARD
2002/04/23 SUPPL-30（补充） Approval Manufacturing (CMC) STANDARD
2002/03/11 SUPPL-27（补充） Approval Manufacturing (CMC) STANDARD
2002/01/08 SUPPL-29（补充） Approval Labeling STANDARD
2001/12/04 SUPPL-28（补充） Approval Labeling STANDARD
2001/03/21 SUPPL-26（补充） Approval Labeling STANDARD
2001/01/23 SUPPL-25（补充） Approval Labeling STANDARD
2000/11/09 SUPPL-24（补充） Approval Manufacturing (CMC) STANDARD
2000/07/26 SUPPL-6（补充） Approval Labeling STANDARD
2000/06/01 SUPPL-23（补充） Approval Labeling STANDARD
2000/06/01 SUPPL-19（补充） Approval Labeling STANDARD
2000/06/01 SUPPL-17（补充） Approval Labeling STANDARD
2000/06/01 SUPPL-16（补充） Approval Labeling STANDARD
2000/06/01 SUPPL-15（补充） Approval Labeling STANDARD
2000/04/10 SUPPL-22（补充） Approval Manufacturing (CMC) STANDARD
1999/11/30 SUPPL-21（补充） Approval Manufacturing (CMC) STANDARD
1999/09/23 SUPPL-18（补充） Approval Manufacturing (CMC) STANDARD
1999/09/09 SUPPL-20（补充） Approval Labeling STANDARD
1999/01/27 SUPPL-13（补充） Approval Manufacturing (CMC) STANDARD
1998/03/31 SUPPL-11（补充） Approval Labeling STANDARD
1997/08/06 SUPPL-12（补充） Approval Labeling STANDARD
1997/05/05 SUPPL-10（补充） Approval Labeling STANDARD
1997/05/05 SUPPL-9（补充） Approval Labeling STANDARD
1997/02/06 SUPPL-5（补充） Approval Manufacturing (CMC) STANDARD
1997/01/13 SUPPL-7（补充） Approval Manufacturing (CMC) STANDARD
1996/12/02 SUPPL-8（补充） Approval Manufacturing (CMC) STANDARD
1996/06/25 SUPPL-3（补充） Approval Labeling STANDARD
1996/03/28 SUPPL-4（补充） Approval Manufacturing (CMC) STANDARD
1996/03/28 SUPPL-1（补充） Approval Manufacturing (CMC) STANDARD
1996/03/20 SUPPL-2（补充） Approval Manufacturing (CMC) STANDARD
1994/12/22 ORIG-1（原始申请） Approval Type 1 - New Molecular Entity STANDARD
与本品相关的专利信息（来自FDA橙皮书Orange Book）
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
无
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
无
与本品治疗等效的药品
本品无治疗等效药品
更多信息
药品NDC数据与药品包装、标签说明书
参考引用1
参考引用2
©2006-2024 DrugFuture->U.S. FDA Drugs Database